China Times (www.chinatimes.net.cn) reporter Wang Yu Yu Na reported in Beijing
htmlOn October 14, the long-silent pharmaceutical stocks launched a large counterattack. The WIND index on the same day showed that the pharmaceutical index rose by 6.47%, the largest increase in since this year . Among the 240 pharmaceutical companies, only 4 fell, 26 stocks with an increase of more than 9%, and 51 stocks with an increase of more than 5%.Industry insiders pointed out that the recent breakthrough progress of innovative drugs combined with the significant increase in performance of leading companies in the first three quarters has led to a significant increase in confidence in the capital market.
Leading company for innovative drugs BeiGene disclosed on the evening of October 12 that the core product Zebutinib has made breakthrough progress in the "head-to-head" trial with idbutinib, which marks the further development of this innovative drug going overseas. BeiGene Public Relations Department told the reporter of " China Times " that it has submitted a new indication listing application for Zebutinib for chronic lymphocytic leukemia to FDA. The target time for the FDA to make a decision is January 20, 2023.
, led by BeiGene, innovative drugs have wiped out the decline this year, and the innovative drug index rose by 6.43% today.
In addition, among the 23 pharmaceutical companies that disclosed their performance forecasts for the first three quarters, 19 companies' performance increased, and WuXi AppTec led the growth rate of net profit of 107.12% in the first three quarters, boosting confidence in the market.
Regarding the performance of pharmaceutical companies in the capital market, Southwest Securities Du Xiangyang's team said that the recent valuation of the pharmaceutical sector (TTM is 23 times) and holdings (excluding active pharmaceutical funds in 22Q2 account for 6.94%) are both at the historical bottom. In addition, the policy expectations are mild, so it is worth paying attention to in the future.
stock price counterattack
On the last trading day of this week, the stock price of pharmaceutical companies led the big A. As of today's closing, the WIND Pharmaceutical Index rose 6.47%, the largest increase since the year. Of the 240 pharmaceutical companies, only 4 fell. There are 26 stocks with an increase of more than 9%, and 51 stocks with an increase of more than 5%. Among them, Hengrui Medicine , WuXi AppTec, Kailaiying , Renfu Pharmaceutical and other daily limit hits; Kanglong Chemical's increase was 15.43%, Boteng Co., Ltd. , Tiger Pharmaceutical , and Beida Pharmaceutical followed closely, all of which exceeded 13%.
WIND Medical Device Select Index rose 10.86%, and all 46 stocks rose. Among them, 7 stocks had a 20% increase, and the medical device leader Mindray Medical rose 13.64%.
According to the sub-sectors, CRO companies rose fiercely today, with the index rising by 8.24%, WuXi AppTec and Kelley Ying hit the daily limit, Kanglong Huacheng rose by 15.43%, Boteng Co., Ltd. and Tiger Pharmaceuticals rose by more than 13%; the innovative drug index rose by 6.43%, Hengrui Pharmaceuticals, Beida Pharmaceuticals, Zhifei Biologics, and Changchun Hi-Tech led the rise, and BeiGene, the leading innovative drug company, rose by 5.76% today, and rose by 13.51% yesterday.
Southwest Securities Du Xiangyang's team said that the recent valuation of the pharmaceutical sector (TTM is 23 times) and holdings (excluding active pharmaceutical funds in 22Q2 account for 6.94%) are both at the historical bottom. In addition, the policy expectations are mild, so we can focus on the three major sectors: new medical infrastructure, time-travel medical insurance, and epidemic recovery. Regarding today's pharmaceutical stock counterattack, some industry insiders said that the recent breakthrough progress of innovative drugs and the significant increase in performance of leading companies in the first three quarters have led to a significant increase in market confidence.
has been positive for the whole time
On the evening of October 12, BeiGene-U (688235.SH) disclosed an announcement stating that the company's independently developed product BTK inhibitor Baeze® (Zebutinib Capsules) in a final analysis of the global Phase 3 ALPINE trial, Zebutinib compared idbutinib achieved a progress-free survival (PFS). The results showed that Zebutinib capsules were generally tolerated well, and the safety results shown in this analysis were consistent with previous reports.
In other words, Zebutinib became the world's first "head-to-head" trial of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), successfully challenging idrutinib and achieving excellent results in progression-free survival.
"Head-to-Head Trial" refers to a non-placebo-controlled trial. It conducts clinical trials based on clinically used therapeutic drugs or treatment methods, with the purpose of conducting more detailed research and comparison of the efficacy or safety of drugs.The success of
Zebutinib means that innovative drugs have taken a step forward in going overseas. BeiGene's Public Relations Department told the reporter of the China Times that it had previously submitted an application for the launch of Zebutinib for chronic lymphocytic leukemia to the FDA, and the target time for the FDA to make a decision is January 20, 2023.
Affected by this positive news, BeiGene's stock price rose 13.51% on October 13, and continued to rise on October 14, closing at 101.20 yuan per share. In addition to the breakthrough progress in innovative drugs,
has also continued to improve in the first three quarters of this year.
According to WIND data, as of October 14, a total of 23 pharmaceutical companies disclosed their third-quarter financial reports. Among them, 19 companies expected to increase, continue to earn and slightly increase, and only two companies that continued to lose are Microelectrophysiology-U and Northland . Nocheng Jianhua-U lost the first loss, and nearshore protein decreased slightly.
Among the companies with significant performance growth, BGI Intelligent Manufacturing disclosed in its August prospectus that the net profit growth rate in the first three quarters of this year was 311.80%-340.08%, currently ranks first.
In addition, among the companies that recently disclosed their third-quarter financial reports, the leading company WuXi AppTec led with a net profit growth rate of 107.12%. WuXi AppTec's main business is to provide integrated, end-to-end new drug research and development and production services for the global biomedical industry.
Regarding the reasons for the increase in performance, WuXi AppTec stated that the company continues to strengthen WuXi AppTec's unique integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models; under the influence of the continuous and repetitive epidemics in many places, it will give full play to the advantages of global layout, operations in many places and coverage of the entire industrial chain, and timely formulate and efficiently implement business continuity plans to ensure the company's overall performance goals. The company is confident that it will achieve the annual revenue growth target of 68%-72% for 2022. On October 13, after the disclosure of
's performance, WuXi AppTec's share price rose 5.44%, hitting the daily limit this Friday, closing at 80.96 yuan per share. Wantai Bio is the second largest net profit growth rate in
. The performance forecast stated that Wantai Bio's net profit attributable to shareholders increased by 216% to 232% year-on-year. Regarding the reasons for the increase in performance, the company said, "The company's bivalent cervical cancer vaccine continues to maintain both production and sales, and revenue and profits have grown rapidly; due to the impact of the new crown pneumonia epidemic at home and abroad, the company's revenue and profits of new crown raw materials and new crown testing reagents have achieved rapid growth."
With the breakthrough progress in innovative drugs and the performance of pharmaceutical companies in the first three quarters, pharmaceutical stocks may surpass the "cold winter".
Intern editor: Yan Yuan Editor-in-chief: Chen Yanpeng
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-